Market Overview

UPDATE: Deutsche Bank Ups PT to $45 on Medtronic on Top-Line Beat

Share:
Related MDT
What Specific Role Will Apple Play In IBM's Watson Health Cloud Alliance?
The Big Health Data Orgy Happening In The Cloud
FDA clears Medtronic balloon dilation catheter (Seeking Alpha)

Deutsche Bank reiterated its Hold rating on Medtronic (NYSE: MDT) and raised its price target from $43 to $45.

Deutsche Bank noted, "In F2Q13, Medtronic's sales grew 5% ex-FX driven by the successful launch and share gains in the drug-eluting stent business (which accounted for 1.6%-pts of growth). While sales were better, EPS was in-line with Consensus ($0.01 below our estimate) due mainly to lower gross margins. Medtronic managed the P&L noting it took one-time gains from selling treasuries and minority investments to help offset FX hedging losses. We maintain our Hold rating but we are slightly increasing our PT to $45 from $43 given the more stable top line performance in the quarter and expectations going forward."

Medtronic closed at $42,65 on Tuesday.

Latest Ratings for MDT

DateFirmActionFromTo
Mar 2015BMO CapitalMaintainsOutperform
Feb 2015JefferiesMaintainsBuy
Dec 2014Bank of AmericaMaintainsBuy

View More Analyst Ratings for MDT
View the Latest Analyst Ratings

Posted-In: Deutsche BankAnalyst Color Price Target Intraday Update Analyst Ratings

 

Related Articles (MDT)

Around the Web, We're Loving...